BioCentury | Jun 9, 2020
Product Development

Lilly’s Junshi-partnered program becomes China’s first COVID-19 mAb in clinic

As EMA nears a decision on Gilead’s remdesivir to treat COVID-19 and a pair of groups take steps towards making vaccines available in the U.K., a second mAb against SARS-CoV-2 has entered clinical testing. Eli...
BioCentury | Jun 4, 2020
Management Tracks

Giroir stepping down as COVID-19 testing czar; plus Gilead, Sanofi Ventures, Varian, Sirtex and Oxford BioMedica

Brett Giroir, who was appointed in March to coordinate the U.S.’s COVID-19 testing efforts, will be “demobilized” from his post mid-June and return to his previous position as assistant secretary for health and head of...
BioCentury | May 2, 2020
Product Development

Daily Chart: Oxford’s global network of COVID-19 vaccine manufacturing sites

To meet demand as much demand for its COVID-19 vaccine as quickly as possible, the University of Oxford has been building a coalition of manufacturing partners before it even knows if the vaccine works. The...
BioCentury | Apr 30, 2020
Deals

AstraZeneca to make COVID-19 vaccine with roots in Oxford’s CEPI-funded MERS project

When the first therapies and vaccines for COVID-19 are approved, it is likely that they will be the result of responses to prior viral outbreaks and pandemic preparedness programs. Products that will be hailed as...
BioCentury | Feb 11, 2020
Product Development

Adverum gains on Phase I data showing efficacy for wet AMD gene therapy

Updated interim data for Adverum’s intravitreal wet age-related macular degeneration gene therapy bolstered the company’s case that the product could compete with less convenient subretinal gene therapies for the indication. Adverum rose $1.81 (18%) to...
BC Extra | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

Wave Life Sciences Ltd. (NASDAQ:WVE) disclosed in an SEC filing that CFO Keith Regnante stepped down to pursue other opportunities. VP and Corporate Controller David Gaiero will serve as interim CFO, principal accounting officer and...
BC Innovations | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump...
BC Innovations | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
BC Extra | Jun 26, 2019
Company News

June 26 Company Quick Takes: Dupixent approved for nasal polyps; plus Ono/Rafael, Oxford/Santen and more

FDA approves Regeneron's Dupixent in nasal polyps  FDA approved Dupixent dupilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat chronic rhinosinusitis with nasal polyps. Dupixent is the first drug approved for the indication (see "Phase III...
BC Extra | Jun 17, 2019
Company News

Sanofi shies away from neuro gene therapy programs

Changes to two partnerships this year suggest Sanofi is paring down the disease areas in which it wants to deploy gene therapy. The latest came on Monday, when Voyager Therapeutics Inc. (NASDAQ:VYGR) said it and...
Items per page:
1 - 10 of 416
BioCentury | Jun 9, 2020
Product Development

Lilly’s Junshi-partnered program becomes China’s first COVID-19 mAb in clinic

As EMA nears a decision on Gilead’s remdesivir to treat COVID-19 and a pair of groups take steps towards making vaccines available in the U.K., a second mAb against SARS-CoV-2 has entered clinical testing. Eli...
BioCentury | Jun 4, 2020
Management Tracks

Giroir stepping down as COVID-19 testing czar; plus Gilead, Sanofi Ventures, Varian, Sirtex and Oxford BioMedica

Brett Giroir, who was appointed in March to coordinate the U.S.’s COVID-19 testing efforts, will be “demobilized” from his post mid-June and return to his previous position as assistant secretary for health and head of...
BioCentury | May 2, 2020
Product Development

Daily Chart: Oxford’s global network of COVID-19 vaccine manufacturing sites

To meet demand as much demand for its COVID-19 vaccine as quickly as possible, the University of Oxford has been building a coalition of manufacturing partners before it even knows if the vaccine works. The...
BioCentury | Apr 30, 2020
Deals

AstraZeneca to make COVID-19 vaccine with roots in Oxford’s CEPI-funded MERS project

When the first therapies and vaccines for COVID-19 are approved, it is likely that they will be the result of responses to prior viral outbreaks and pandemic preparedness programs. Products that will be hailed as...
BioCentury | Feb 11, 2020
Product Development

Adverum gains on Phase I data showing efficacy for wet AMD gene therapy

Updated interim data for Adverum’s intravitreal wet age-related macular degeneration gene therapy bolstered the company’s case that the product could compete with less convenient subretinal gene therapies for the indication. Adverum rose $1.81 (18%) to...
BC Extra | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

Wave Life Sciences Ltd. (NASDAQ:WVE) disclosed in an SEC filing that CFO Keith Regnante stepped down to pursue other opportunities. VP and Corporate Controller David Gaiero will serve as interim CFO, principal accounting officer and...
BC Innovations | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump...
BC Innovations | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
BC Extra | Jun 26, 2019
Company News

June 26 Company Quick Takes: Dupixent approved for nasal polyps; plus Ono/Rafael, Oxford/Santen and more

FDA approves Regeneron's Dupixent in nasal polyps  FDA approved Dupixent dupilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat chronic rhinosinusitis with nasal polyps. Dupixent is the first drug approved for the indication (see "Phase III...
BC Extra | Jun 17, 2019
Company News

Sanofi shies away from neuro gene therapy programs

Changes to two partnerships this year suggest Sanofi is paring down the disease areas in which it wants to deploy gene therapy. The latest came on Monday, when Voyager Therapeutics Inc. (NASDAQ:VYGR) said it and...
Items per page:
1 - 10 of 416